fbpx
March 3, 2023

FDA Official Who Oversaw Aducanumab Approval Retiring FDA Official Who Oversaw Aducanumab Approval Retiring

A US Food and Drug Administration (FDA) official who oversaw the approval of the controversial Alzheimer’s therapy aducanumab (Aduhelm) is retiring from the agency to ‘explore […]
March 2, 2023

Tirofiban Superior to Aspirin in Stroke Without Large Occlusion Tirofiban Superior to Aspirin in Stroke Without Large Occlusion

New research suggests some patients do better with tirofiban (Aggrastat) than with low-dose aspirin following disabling stroke without a visible large or medium intracranial vessel occlusion. […]
March 2, 2023

‘Havana Syndrome’ Not Caused by Foreign Adversary, US Intel Finds ‘Havana Syndrome’ Not Caused by Foreign Adversary, US Intel Finds

MCLEAN, Virginia (Reuters) – A globe-spanning U.S. intelligence investigation has concluded it is “very unlikely” a foreign adversary is responsible for the “Havana syndrome” ailment that […]
March 1, 2023

Any Level of Physical Activity Tied to Better Later-Life Memory Any Level of Physical Activity Tied to Better Later-Life Memory

Any amount of exercise in middle age is associated with better cognition in later life, new research suggests. A prospective study of 1400 participants showed that […]
March 1, 2023

Childhood Trauma Tied to Increased Parkinson’s Disease Severity Childhood Trauma Tied to Increased Parkinson’s Disease Severity

Adverse childhood experiences (ACEs) are associated with increased motor and nonmotor symptoms of Parkinson’s disease (PD) and reduced quality of life (QOL), new research shows. Results […]
March 1, 2023

Don’t Dismiss MS as a Diagnosis in Minorities, Experts Warn Don’t Dismiss MS as a Diagnosis in Minorities, Experts Warn

SAN DIEGO ― Experts are leading a new initiative to drive home the message that clinicians must consider multiple sclerosis (MS) in the differential diagnosis of […]
March 1, 2023

FDA OKs First Treatment for Friedreich’s Ataxia FDA OKs First Treatment for Friedreich’s Ataxia

The US Food and Drug Administration (FDA) has approved the first treatment for the neurodegenerative disorder Friedreich’s ataxia for use in adults and adolescents aged 16 […]
February 28, 2023

Cutting Calories May Benefit Cognition in MS Cutting Calories May Benefit Cognition in MS

Weight loss from intermittently cutting calories has a positive effect on cognitive, immunologic, and other outcomes for patients with multiple sclerosis (MS), new research suggests. Dr […]
February 28, 2023

High Level of Psychiatric Morbidity in Prodromal MS High Level of Psychiatric Morbidity in Prodromal MS

SAN DIEGO — The prevalence of psychiatric morbidity is significantly higher among patients with multiple sclerosis (MS) vs controls in each of the 5 years prior […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0